98%
921
2 minutes
20
Accurate classification of melanocytic proliferations has important implications for prognostic prediction, treatment and follow-up. Although most melanocytic proliferations can be accurately classified using clinical and pathological criteria, classification (specifically distinction between nevus and melanoma) can be challenging in a subset of cases, including those with spitzoid morphology. Genetic studies have shown that mutation profiles differ between primary melanoma subtypes and Spitz nevi. These differences may aid in distinguishing benign from malignant in some melanocytic tumours. Here, we present a selection of melanocytic proliferations with equivocal histopathological criteria, wherein genetic analysis was requested to help guide classification. In two of four cases, the genetic results offered valuable insights, allowing a definitive diagnosis, indicating the diagnostic value of mutation profiling in a real-world routine clinical setting. Although histopathological assessment remains decisive in melanocytic proliferation classification, we recommend including genetic profiling in cases of borderline or atypical lesion to support accurate classification.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087654 | PMC |
http://dx.doi.org/10.1016/j.ejca.2021.02.025 | DOI Listing |
NAR Cancer
September 2025
Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany.
Germline mutations in the DNA repair helicase XPD can cause the diseases xeroderma pigmentosum (XP) and trichothiodystrophy (TTD). XP patients bear an increased risk of skin cancer including melanoma. This is not observed for TTD patients despite DNA repair defects.
View Article and Find Full Text PDFJ Skin Cancer
August 2025
Department of Dermatology, University Medical Center Mannheim, Heidelberg University, Mannheim, Baden-Württemberg, Germany.
Corticotropin-releasing hormone (CRH) regulates immunological and cellular processes. Recently, CRH is expressed in skin cancers, where its expression appears to correlate with the degree of malignancy. This study correlates CRH expression in melanoma metastases with patient survival and compares the intensity of CRH expression in melanoma to that in less aggressive skin cancer entities.
View Article and Find Full Text PDFInt Immunopharmacol
September 2025
The Key Laboratory of Molecular Biology of Infectious Diseases designated by the Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, China. Electronic address:
Melanoma is an aggressive malignancy originating from melanocytes, marked by its high metastatic potential, severe malignancy, and poor prognosis. The primary clinical approach involves surgical resection, complemented by adjuvant therapies such as radiotherapy, chemotherapy, targeted therapies, and immunotherapies. In recent years, high-dose IFNα2b has emerged as a pivotal adjuvant therapy following surgery.
View Article and Find Full Text PDFAm J Dermatopathol
September 2025
Department of Dermatology and Cutaneous Surgery, University of South Florida, Tampa, FL.
Background: Recurrent melanocytic nevi are benign melanocytic proliferations that occur after incomplete excision of a nevus. Their atypical clinical and histopathologic features complicate diagnosis, especially without knowledge of prior biopsy. The PRAME (PReferentially expressed Antigen in MElanoma) immunohistochemical stain has been increasingly used to support a diagnosis of melanoma, however, its utility in recurrent melanocytic nevi is not well established.
View Article and Find Full Text PDFExp Dermatol
September 2025
Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Acral melanoma (AM) is a rare subtype of cutaneous melanoma mainly found in acral locations. The treatment of advanced AM remains challenging due to its rarity and the distinct features of this subtype compared with the other common types of melanomas. There is thus an urgent need to develop effective therapeutic approaches for AM.
View Article and Find Full Text PDF